Loading clinical trials...
Loading clinical trials...
This is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study evaluating the efficacy and safety of IBI362 in overweight or obese subjects. Subjects will be randomly ass...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Innovent Biologics (Suzhou) Co. Ltd.
NCT06937086 · Ulcerative Colitis, Obesity or Overweight
NCT07351045 · Obesity or Overweight
NCT07255209 · Adolescents With Obesity or Overweight With Weight-Related Comorbidities
NCT07128888 · Obesity or Overweight
NCT06862791 · Obesity or Overweight
Xuancheng People's Hospital
Xuancheng, Anhui
People's Hospital of Peking University
Beijing, Beijing Municipality
Luoyang Third People's Hospital
Luoyang, He'nan
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions